The Zacks Analyst Blog Highlights:Tesla Motors, Allergan, Sanofi, Actavis and Mallinckrodt

CHICAGO, Feb. 4, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Tesla Motors, Inc. (Nasdaq: TSLA-Free Report), Allergan Inc. (NYSE: AGN-Free Report), Sanofi (NYSE: SNY-Free Report), Actavis plc (NYSE: ACT-Free Report) and Mallinckrodt plc (NYSE: MNK-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday's Analyst Blog:

Tesla Sets Cross-Country EV Record

A team sent by Tesla Motors, Inc. (Nasdaq: TSLA-Free Report) has completed the journey from Los Angeles to New York, setting a record for the lowest charge time for an electric vehicle traveling across the country. The team traveled in two Tesla Model S cars and relied solely on Tesla's Supercharger network during the cross-country drive. As a result, the team incurred zero fuel cost.

Tesla is hopeful of getting recognition from the Guinness World Records for the feat. The 3,464.5 mile journey was completed by the team in 76.5 hours.

The journey was an excellent marketing strategy implemented by Telsa to highlight the recent completion of its first cross-country Supercharger route. The drive displayed the efficiency of the Supercharger network in terms of saving both time and cost.

Last week, a father-daughter duo beat team Tesla becoming the first to complete the coast-to-coast journey using Superchargers. However, they took almost 6 days to complete the journey.

Tesla's Superchargers not only provide free charging to Model S owners, but also charge faster than normal electric charging stations. They can restore half the battery charge in just 20 minutes, while normal charging stations take as much as 9 hours for a full charge.

Tesla currently has over 70 Superchargers in North America and is expanding the network fast. The company recently also completed the feat of having at least one car registered in all 50 states of the U.S.

In a separate news, Tesla will soon open its first store in Contra Costa County, according to Contra Costa Times. The electric carmaker has seven other stores in the Bay Area.

Tesla currently carries a Zacks Rank #1 (Strong Buy).

Is Allergan (AGN) Poised to Beat Earnings Estimates?

Allergan Inc. (NYSE: AGN-Free Report) is scheduled to report fourth quarter 2013 results before the opening bell on Feb 5.

Last quarter, Allergan had posted an earnings surprise of +1.65%. We expect the company to beat expectations in the fourth quarter as well.

Why a Likely Positive Surprise?

Our proven model shows that Allergan is likely to beat earnings because it has the right combination of two key ingredients.

Positive Zacks ESP: The Earnings ESP (Expected Surprise Prediction), which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +0.75%. This is a very meaningful and leading indicator of a likely positive earnings surprise.

Zacks Rank #2 (Buy): Note that stocks with Zacks Rank #1, #2 and #3 have a significantly higher chance of beating earnings estimates. We caution against stocks with Zacks Ranks #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revision momentum.

The combination of Allergan's Zacks Rank #2 (Buy) and an earnings ESP of +0.75% makes us confident of an earnings beat on Feb 5.

What is Driving the Better-than-Expected Earnings?

Allergan has delivered positive earnings surprises in the last three quarters with an average beat of 1.80%.

Botox and Restasis should continue to boost revenues. The specialty pharmaceuticals segment should see strong sales and facial aesthetics should also perform well.

Other Stocks to Consider

Allergan is not the only company looking up this earnings season. We also see likely earnings beats coming from these companies in the health care sector:

Sanofi (NYSE: SNY-Free Report) has an earnings ESP of +2.27% and holds a Zacks Rank #3. Sanofi will report fourth quarter earnings on Feb 6.

Actavis plc (NYSE: ACT-Free Report) has an earnings ESP of +0.66% and holds a Zacks Rank #1 (Strong Buy). Actavis will be reporting fourth quarter earnings on Feb 20.

Mallinckrodt plc (NYSE: MNK-Free Report) has an earnings ESP of +4.69% and holds a Zacks Rank #2 (Buy). Mallinckrodt will report first quarter fiscal 2014 earnings on Feb 6.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on TSLA - FREE

Get the full Report on AGN - FREE

Get the full Report on SNY - FREE

Get the full Report on ACT - FREE

Get the full Report on MNK - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

SOURCE Zacks Investment Research, Inc.



RELATED LINKS
http://www.zacks.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.